VITRAKVI
Active substance: larotrectinib
CAPSULE · LAROTRECTINIB 25 mg/1
United StatesActive
Marketing holder: Loxo Oncology, Inc.
Verified 2026-10-09 · openFDA NDC
Analogues in other countries- Source: openFDA NDC
- Countries with the substance registered: 2
Composition
- LAROTRECTINIB · 25 mg/1
Analogues by country
Products with the same active substance registered in other countries.
| Country | Products |
|---|---|
| EU 1 |
|
Import and control
Control by country
- United Statesprescription only
Source: openFDA NDC · record 01a1208c-6c4b-7f36-b62c-4a769162e6f5,01a1208d-b6a7-708f-af6f-829aa231eb41,01a12093-9744-79b1-9b31-3ad438b63e3b,01a12098-bcaa-7831-ac9a-ab94be027931,01a12099-acad-7083-b6e2-904e71f80e9f;count=7 · valid from 2026-10-09 · verified 2026-10-09
Registration
- Registration number
- 71777-390
- Registration status
- Active
- Dispensing
- Prescription only
- Route
- ORAL
Sources
- product · openFDA NDC · 71777-390 · Verified 2026-10-09 · open in source
- registration_status · openFDA NDC · 71777-390 · Verified 2026-10-09 · open in source
- ingredients.0 · openFDA NDC · 71777-390 · Verified 2026-10-09 · open in source